Subscribe
shutterstock_1349383838_thomas_quack
Thomas Quack / Shutterstock.com
22 October 2019AmericasSarah Morgan

CRISPR Therapeutics to buy JV from Bayer

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?